•
China-based Acotec Scientific Holdings Ltd (HKG: 6669) and US major Boston Scientific Corporation (NYSE: BSX) entered into a partial acquisition offer and collaboration agreement. According to the offer, Boston Scientific will acquire up to 203.7 million of Acotec’s shares at HKD 20 (USD 2.57) apiece, amounting to a 65% stake.…
•
US major Biogen’s (NASDAQ: BIIB) Alzheimer’s disease (AD) therapy aducanumab has been administered to a Chinese patient for the first time via the Hainan branch of Ruijin Hospital. The hospital is part of the Boao Lecheng medical pilot zone in Hainan province. Aducanumab: FDA Approval and IndicationAducanumab, a beta amyloid…
•
Stemirna Therapeutics Co., Ltd, an mRNA drug developer based in Shanghai, has obtained Emergency Use Authorization (EUA) in Laos for its in-house developed COVID-19 mRNA vaccine, used for people aged 18 and above to prevent COVID-19 pneumonia through active immunization. The product, the first home-grown COVID-19 mRNA vaccine approved in…
•
Sipai Health Technology Co., Ltd, also known as Medbanks, is set to make an initial public offering (IPO) of 9.92 million shares to the Hong Kong Stock Exchange (HKSE), priced at HKD 18.6 (USD 2.39) per share. The online health platform expects to take home HKD 184 million (USD 23.66…
•
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) announced the completion of the enrollment of all subjects and their clinical observation, alongside the clinical study summary report of a Phase I clinical study for its Category 1 GST-HG171. The results showed that GST-HG171 had good safety, tolerability, and pharmacokinetics, which…
•
China-based Alphamab Oncology (HKG: 9966) updated the clinical studies for its KN046 and KN026 at the San Antonio Breast Cancer Symposium 2022 annual meeting. KN046/Albumin Paclitaxel in Metastatic TNBCThe Phase II clinical trial is designed to evaluate the efficacy, safety, and tolerability of KN046 combined with albumin paclitaxel in the…
•
Swiss giant Roche’s (SWX: ROG) China unit and Roche Diagnostics’ China unit entered into a cooperation memorandum of understanding (MoU) with Shanghai’s Class 3A Zhongshan Hospital, a major teaching hospital affiliated to China’s National Health Commission. The three entities will collaborate on clinical studies in cancer and other diseases, create…
•
The American Society of Hematology (ASH) 2022 annual meeting, held online and offline in New Orleans, Louisiana, USA, saw the latest updates from a string of China-based biotechs. Those included CARsgen Therapeutics Holdings Ltd (HKG: 2171), Gracell Biotechnologies Inc (Nasdaq.GRCL), Innovent Biologics Inc., (HKG: 1801), Junshi Biosciences (HKG: 1877, SHA:…
•
Germany giant Merck (NYSE: MRK) struck a three-year partnership with Tsinghua Shenzhen International Graduate School, with a focus on the development of a new organoid 3D printing system. The tie-up is designed to develop bioengineering-based technologies to enable high-throughput and standardized organoid applications in academic research and the pharmaceutical industry.…
•
China-based Luye Pharma Group announced that it is handing Singapore distribution and marketing rights to the schizophrenia drug Seroquel (quetiapine fumarate immediate-release tablets) and Seroquel sustained release tablets to DCH Auriga. No financials were disclosed. Acquisition and Licensing HistoryLuye acquired exclusive rights to Seroquel from AstraZeneca via a USD 546…
•
China-based RemeGen Ltd announced that its antibody drug conjugate (ADC) drug candidate RC118 has obtained two orphan drug designations (ODD) from the US FDA, for the therapy’s potential use against gastric and pancreatic cancers. RC118: Mechanism and DevelopmentRC118, a novel ADC drug candidate co-developed with contract research organization (CRO) Biocytogen,…
•
China-based Innovent Biologics Inc. (HKG: 1801) announced the presentation of two clinical studies at the 2022 European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO). IBI939 Phase Ib Study ResultsA Phase Ib study to evaluate the safety, tolerability, and efficacy of anti-TIGIT candidate IBI939 in combination with sintilimab in patients with…
•
Science Standard Medical Testing, a professional third-party testing institution based in Changzhou, reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round, a private funding backed by Suzhou Xilu Venture Capital Partnership Limited. Ascendin Fund supported the company’s previous angel financing. Company Background and ServicesFounded in 2015,…
•
Sino-US biotech Phanes Therapeutics Inc. announced a clinical study cooperation and supply agreement with China-based biotech BeiGene (HKG: 6160, SHA: 688235, Nasdaq: BGNE) to carry out a Phase I clinical study assessing the safety and efficacy of Phanes’ PT199 combined with BeiGene’s tislelizumab in multiple advanced solid tumors. PT199: Mechanism…
•
Sino-US artificial intelligence (AI) firm XtalPi Inc. struck a partnership with China-based Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177). The two will work together on the development of small-molecule drugs in the liver disease field. No financial details were disclosed. AI…
•
Harbour BioMed (HBM; HKG: 2142), a biotech operating out of the United States, the Netherlands, and Suzhou (China), announced the conclusion of a Phase I clinical study for its anti-CTLA-4 antibody HBM4003 combined with Junshi Bio’s programmed death-1 (PD-1) inhibitor Tuoyi (toripalimab) in advanced melanoma. The study has shown that…
•
China-based Frontier Biotechnologies Inc. (SHA: 688221) announced a strategic collaboration agreement with compatriot firm Jiangsu Yuyue Medical Equipment Inc. (SHE: 002223). Yuyue Med will supply Frontier Bio the atomizer of the designated model used in the early clinical trials of the FB2001 atomized inhalant bofutrelvir at a discounted price, alongside…
•
Harbour BioMed (HKG: 2142), a biotech operating out of the Netherlands, the United States, and China, announced that its wholly-owned subsidiary Nona Biosciences entered into a licensing agreement with China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Kelun-Biotech will obtain rights to utilize Nona Bio’s proprietary All H2L2 transgenic Harbour Mice platform…
•
ExoNeuglia, a stem-cell-focused biotech based in Suzhou, reportedly raised “tens of millions” of renminbi in an angel financing round, solely backed by RedHill Capital. The company is self-described as the first domestic cell therapy company utilizing induced pluripotent stem cells (iPSCs) technology to treat demyelinating diseases. Demyelinating Diseases and Treatment…
•
The Center for Drug Evaluation (CDE) website indicates that China-based Jacobio Pharmaceuticals Group Co., Ltd’s (HKG: 1167) KRAS G12C inhibitor JAB-21822 has received breakthrough therapy designation (BTD) status for its potential as a treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with KRAS p.G12C mutation. The…